Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Elraglusib by Actuate Therapeutics for Neuroblastoma: Likelihood of Approval
Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II...
Elraglusib by Actuate Therapeutics for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According...
Elraglusib by Actuate Therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to...
Elraglusib by Actuate Therapeutics for Myelofibrosis: Likelihood of Approval
Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...
Elraglusib by Actuate Therapeutics for Pancreatic Cancer: Likelihood of Approval
Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...